Neptra

1 x 2 pc

Ear drops, solution

Active substance

Florfenicol : 16,7 mg/dosis

Terbinafine (Terbinafine hydrochloride) : 16,7 mg/dosis

Mometasone (Mometasone furoat) : 2,2 mg/dosis

ATC code

QS02CA91 Mometasone (Corticosteroids - potent (group III)) and anti-infectives

QS02CA Corticosteroids and antiinfectives in comb.

QS02C Corticosteroids and antiinfectives in comb.

QS02 Otologicals

QS Sensory organs

Species

Dogs

Indications

For the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis).

Dose to be administered and administration route

Auricular use.

Single treatment

The recommended dosage is 1 single-dose container (i.e. 1 ml of solution) per infected ear. The maximum clinical response may not be seen until 28 days after administration.

Shake well before use for 5 seconds.

Clean and dry the external ear canal before administering the product.

While holding the single-use container in an upright position, remove the cap. Use the upper end of the cap to completely break the seal and then remove cap from the single-use container.

Screw the applicator nozzle onto the single-use container.

Insert the applicator nozzle into the affected external ear canal and squeeze the entire contents into the ear.

Gently massage the base of the ear for 30 seconds to allow distribution of the solution. Restrain the dog’s head to prevent shaking, for 2 minutes.

Adverse reactions

Dog

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Application site erythema, Application site inflammation, Application site pain¹

Hyperactivity,

Vocalisation¹ Emesis

Deafness², Impaired hearing², Internal ear disorder, Head shake¹

Eye disorder (e.g. blepharospasm, conjunctivitis, corneal ulcer, eye irritation, keratoconjunctivitis sicca)

Ataxia, Nystagmus

Anorexia

¹Observed to occur shortly after product administration.

²Mainly in elderly animals

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.